This Article Full Text (PDF) All Versions of this Article: 1352458506072543v1 13/5/626    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Debouverie, M. Articles by Vespignani, H. Search for Related Content PubMed PubMed Citation Articles by Debouverie, M. Articles by Vespignani, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Chemotherapy Hazardous Substances DB NOVANTRONE Social Bookmarking                         What's this?

Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment

Department of Neurology, Central Hospital, 54000 Nancy, France, m.debouverie{at}chu-nancy.fr, Centre of Clinical Epidemiology, INSERM-DHOS CIE 6, Department of Clinical Epidemiology and Evaluation, Marin Hospital, 54000 Nancy, France

L. Taillandier

Department of Neurology, Central Hospital, 54000 Nancy, France

S. Pittion-Vouyovitch

Department of Neurology, Central Hospital, 54000 Nancy, France

S. Louis

Department of Neurology, Central Hospital, 54000 Nancy, France

H. Vespignani

Department of Neurology, Central Hospital, 54000 Nancy, France

The objectives of this study were to assess the benefits of 1) mitoxantrone after three years of follow-up and 2) disease-modifying treatment (DMT) after stopping mitoxantrone. A retrospective analysis was performed on 304 patients with active relapsing-remitting (RR) or progressive multiple sclerosis (PMS) who were treated with mitoxantrone. After mitoxantrone therapy, some patients received DMT (interferon-beta or glatiramer acetate) while others did not. The disease course of the two groups was evaluated by the Expanded Disability Status Scale (EDSS) before and after mitoxantrone and then every year for three years. The mean EDSS score at starting mitoxantrone and three years after stopping mitoxantrone respectively, were: 3.3 (1.3) and 3.2 (1.7) for the RRMS patients and 5.9 (1.2) and 6.4 (1.4) for the PMS patients. Before starting mitoxantrone, demographic and clinical parameters of predictive disability were not significantly different between patients who received DMT or not. The variation of EDSS between time of stopping mitoxantrone and three years later was significantly different (+0.9 versus +0.3; P=0.03) for patients with RRMS. We found that mitoxantrone treatment induces stable disease up to two years after discontinuation of mitoxantrone therapy. In the third year, patients without DMT deteriorated. Multiple Sclerosis 2007; 13: 626-631. http://msj.sagepub.com

Key Words: clinical follow-up • disease-modifying treatment • mitoxantrone

This version was published on June 1, 2007

Multiple Sclerosis, Vol. 13, No. 5, 626-631 (2007)
DOI: 10.1177/1352458506072543


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M Pascual, N. Tellez, I. Bosca, J. Mallada, A. Belenguer, I. Abellan, A. P Sempere, P. Fernandez, M. J. Magraner, F. Coret, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required Multiple Sclerosis, November 1, 2009; 15(11): 1303 - 1310. [Abstract] [PDF]

				F. Ubiali, S. Nava, V. Nessi, R. Longhi, G. Pezzoni, R. Capobianco, R. Mantegazza, C. Antozzi, and F. Baggi Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats J. Immunol., February 15, 2008; 180(4): 2696 - 2703. [Abstract] [Full Text] [PDF]

				W.-H. Piao, R. Wong, X.-F. Bai, J. Huang, D. I. Campagnolo, R. T. Dorr, T. L. Vollmer, and F.-D. Shi Therapeutic Effect of Anthracene-Based Anticancer Agent Ethonafide in an Animal Model of Multiple Sclerosis J. Immunol., December 1, 2007; 179(11): 7415 - 7423. [Abstract] [Full Text] [PDF]